Published in Dig Dis Sci on July 13, 2006
Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol (2012) 1.50
Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer (2009) 1.10
Liver regeneration and the atrophy-hypertrophy complex. Semin Intervent Radiol (2008) 0.90
Increase in the serum bile acid level predicts the effective hypertrophy of the nonembolized hepatic lobe after right portal vein embolization. World J Surg (2009) 0.78
Can plasma bile salt, triglycerides, and apoA-V levels predict liver regeneration? World J Surg (2012) 0.76
Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study. World J Surg (2012) 0.76
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol (1992) 34.17
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol (1984) 17.76
RELATION OF THE PORTAL BLOOD TO LIVER MAINTENANCE : A DEMONSTRATION OF LIVER ATROPHY CONDITIONAL ON COMPENSATION. J Exp Med (1920) 10.36
Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery (1990) 3.93
Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology (1997) 3.28
Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg (2003) 3.16
Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med (1991) 3.14
Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci U S A (1988) 2.62
Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci U S A (1992) 2.54
Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci U S A (1989) 2.35
Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res (1986) 1.97
Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest (1995) 1.89
Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis. Lancet (1994) 1.55
Atrophy of the liver after occlusion of the bile ducts or portal vein and compensatory hypertrophy of the unoccluded portion and its clinical importance. Gastroenterology (1956) 1.44
Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology (1995) 1.43
Expression of hepatocyte growth factor mRNA in regenerating rat liver after partial hepatectomy. Biochem Biophys Res Commun (1991) 1.33
Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol (1989) 1.33
Modulation of insulin-like growth factor-II/mannose 6-phosphate receptors and transforming growth factor-beta 1 during liver regeneration. J Biol Chem (1991) 1.31
Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta. Cell Regul (1991) 1.27
Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest (1993) 1.18
Right portal vein embolization in preparation for major hepatic resection. J Am Coll Surg (1995) 1.17
Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer (1996) 1.12
Expression of transforming growth factor-alpha in regenerating liver and during hepatic differentiation. Mol Carcinog (1992) 1.09
Ki-67 expression during rat liver regeneration after partial hepatectomy. Hepatology (1997) 1.06
Transforming growth factor-alpha (TGF alpha) concentrations increase in regenerating rat liver: evidence for a delayed accumulation of mature TGF alpha. Endocrinology (1993) 0.98
Possible endocrine control by hepatocyte growth factor of liver regeneration after partial hepatectomy. Biochem Biophys Res Commun (1991) 0.97
Transforming growth factor beta (TGF-beta) inhibits hepatocyte DNA synthesis independently of EGF binding and EGF receptor autophosphorylation. J Cell Physiol (1988) 0.96
Fate of the human liver after hemihepatic portal vein embolization: cell kinetic and morphometric study. Hepatology (1997) 0.96
Transforming growth factor alpha levels in liver and blood correlate better than hepatocyte growth factor with hepatocyte proliferation during liver regeneration. Am J Pathol (1998) 0.90
Choline deficiency causes increased localization of transforming growth factor-beta1 signaling proteins and apoptosis in the rat liver. Pathobiology (1997) 0.89
Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors. J Hepatol (2002) 0.88
Induction of apoptosis by transforming growth factor-beta 1 in the rat hepatoma cell line McA-RH7777: a possible association with tissue transglutaminase expression. Hepatology (1993) 0.84
Expression of hepatocyte growth factor, transforming growth factor alpha, and transforming growth factor beta 1 messenger RNA in various human liver diseases and correlation with hepatocyte proliferation. Hepatology (1996) 0.84
Changes in levels of mRNAs of transforming growth factor (TGF)-beta1, -beta2, -beta3, TGF-beta type II receptor and sulfated glycoprotein-2 during apoptosis of mouse uterine epithelium. J Steroid Biochem Mol Biol (1996) 0.83
Proliferative marker Ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection. Cancer Lett (2002) 0.78
Elevated mitochondrial gene expression during rat liver regeneration after portal vein ligation. Hepatology (1995) 0.77
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med (2007) 12.62
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med (2002) 4.25
Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13
One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Marginal survival benefit in the treatment of early hepatocellular carcinoma. J Hepatol (2012) 2.77
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Nocturnal oxygen desaturation correlates with the severity of coronary atherosclerosis in coronary artery disease. Chest (2003) 2.36
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res (2004) 2.34
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun (2002) 2.13
Regeneration and function of hemiliver graft: right versus left. Surgery (2006) 2.12
Prophylactic impact of endoscopic treatment for esophageal varices in liver resection: a prospective study. J Gastroenterol (2013) 2.08
Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06
High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg (2005) 2.04
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections. World J Surg (2004) 2.04
Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg (2003) 2.04
Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol (2002) 2.03
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg (2003) 2.01
Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg (2003) 2.00
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res (2008) 1.91
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg (2009) 1.87
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res (2012) 1.84
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg (2007) 1.82
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol (2010) 1.79
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res (2012) 1.74
Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol (2006) 1.72
Acute Appendicitis in an Incarcerated Femoral Hernia: A Case of De Garengeot Hernia. Case Rep Gastroenterol (2009) 1.67
Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. J Cardiovasc Electrophysiol (2003) 1.67
Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery (2003) 1.67
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis (2007) 1.60
Refinement of venous reconstruction using cryopreserved veins in right liver grafts. Liver Transpl (2004) 1.59
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer (2011) 1.58
One orifice vein reconstruction in left liver plus caudate lobe grafts. Transplantation (2007) 1.57
Clinical significance of extrahepatic bile duct resection for advanced gallbladder cancer. J Surg Oncol (2006) 1.56
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg (2005) 1.56
Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer (2003) 1.54
S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci (2013) 1.52
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol (2005) 1.52
Portal vein complications after adult-to-adult living donor liver transplantation. Transpl Int (2008) 1.51
Systematic grading of morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.51
Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol (2003) 1.50
Transfusion criteria for fresh frozen plasma in liver resection: a 3 + 3 cohort expansion study. Arch Surg (2011) 1.50
Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg (2002) 1.49
Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma. J Gastroenterol (2004) 1.48
Applicability of enhanced recovery program for advanced liver surgery. World J Surg (2014) 1.48
Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene (2004) 1.46
Ultrasonically assisted retrohepatic dissection for a liver hanging maneuver. Ann Surg (2005) 1.46
Left lobe adult-to-adult living donor liver transplantation: Should portal inflow modulation be added? Liver Transpl (2012) 1.45
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44
Hepatic arterial anatomy for right liver procurement from living donors. Liver Transpl (2004) 1.44
Evaluation of hepatic venous congestion: proposed indication criteria for hepatic vein reconstruction. Ann Surg (2002) 1.43
Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer (2005) 1.42
Two-stage pancreatojejunostomy in pancreaticoduodenectomy: a retrospective analysis of short-term results. Am J Surg (2008) 1.41
Chimeric acceleration by donor CD4+CD25+T-reg depleted fraction in splenocyte transplantation. J Surg Res (2012) 1.41
Bile duct preserving surgery for hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg (2015) 1.41
Could we or should we replace the conventional nomenclature of liver resections? Ann Surg (2013) 1.40
Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol (2007) 1.40
Endoscopic prediction of hepatocellular carcinoma by evaluation of bleeding esophageal varices. Digestion (2004) 1.39
Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg (2004) 1.37
Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol (2009) 1.35
Magnetic resonance findings of bile duct adenoma with calcification. Radiat Med (2006) 1.35
Usefulness of LigaSure for liver resection: analysis by randomized clinical trial. Am J Surg (2006) 1.35
Intraoperative fluorescent cholangiography using indocyanine green: a biliary road map for safe surgery. J Am Coll Surg (2008) 1.34